Roivant Sciences to acquire Silicon Therapeutics to boost drug discovery capabilities
Roivant Sciences has agreed to acquire Silicon Therapeutics, a Boston-based drug design, research, and development company, for $450 million, in an all-share deal. The Swiss biopharma company will also make additional payments to the US firm based on regulatory and commercial milestones. Silicon Therapeutics is said to have developed a computational physics platform. The platform […]